Keros Therapeutics (NASDAQ:KROS) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a hold rating in a research report sent to investors on Thursday,Zacks.com reports.

A number of other research firms have also recently commented on KROS. Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen upgraded Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 24th. Finally, Leerink Partners decreased their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $11.03 on Thursday. The stock has a market capitalization of $218.72 million, a price-to-earnings ratio of -2.98 and a beta of 0.99. Keros Therapeutics has a 52-week low of $9.69 and a 52-week high of $22.55. The stock’s 50 day moving average price is $10.78 and its two-hundred day moving average price is $11.61.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, equities research analysts forecast that Keros Therapeutics will post -5.27 EPS for the current year.

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider owned 27,559 shares in the company, valued at $283,582.11. The trade was a 11.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. This trade represents a 21.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,768 shares of company stock valued at $144,979 in the last three months. 12.60% of the stock is owned by company insiders.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System lifted its holdings in shares of Keros Therapeutics by 72.6% in the second quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock worth $29,000 after buying an additional 1,148 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares during the period. Tower Research Capital LLC TRC grew its stake in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares in the last quarter. Legal & General Group Plc purchased a new position in Keros Therapeutics during the second quarter valued at approximately $90,000. Finally, PDT Partners LLC purchased a new position in Keros Therapeutics during the second quarter valued at approximately $122,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.